The treatment of acute leukemia with continuous infusion L-Alanosine
- 20 Downloads
L-Alanosine, an antitumor antibiotic was administered by members of the Southwest Oncology Group (SWOG) to 22 patients with resistant acute non-lymphocytic leukemia. The drug was administered by continuous infusion for five days at a starting dose of 125 mg/m2/day. Mucositis was dose-limiting in 15 patients and no marrow aplasia was attained. As administered, L-Alanosine is not an effective single agent in acute leukemia.
Key wordsacute leukemia chemotherapy L-Alanosine Phase II
Unable to display preview. Download preview PDF.
- 1.Murthy YKS, Thieman JE, Coronelli C, Sensi P: Alanosine, a new antiviral and antitumor agent isolated from a streptomyces. Nature 211:1198–1199, 1966Google Scholar
- 2.Investigational Drug Branch, CTEP, NCI. Clinical Brochure, L-Alanosine, November, 1977Google Scholar
- 3.Dosik GM, Stewart D, Valdivieso M, Burgess MA, Bodey GP: Phase I study of L-Alanosine using a daily × 3 schedule. Cancer Treat Rep 66:73–76, 1982Google Scholar
- 4.Goldsmith MA, Ohnuma T, Spigelman M, Greenspan EM, Holland JF: Phase I study of L-Alanosine (NSC 15353). Cancer 51:378–380, 1983Google Scholar
- 5.Kovatch J: Phase I Meeting, NCI, March, 1980Google Scholar
- 6.Graff JC, Plagemann PGW: Alanosine toxicity in Novikoff rat hepatoma cells due to inhibition of the conversion of inosine monophosphate to adenosine monophosphate. Cancer Res 36:1428–1400, 1976Google Scholar
- 7.Interim Report, Mayo Clinic, 11/28/80Google Scholar